ArticleInternational journal of molecular sciences2016

Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients.

Tomoko Mizushige et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.